Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.

Creatsa M, Pliatsika P, Kaparos G, Antoniou A, Armeni E, Tsakonas E, Panoulis C, Alexandrou A, Dimitraki E, Christodoulakos G, Lambrinoudaki I.

J Obstet Gynaecol Res. 2011 Oct;37(10):1415-22. doi: 10.1111/j.1447-0756.2011.01557.x. Epub 2011 Jun 9.

PMID:
21651652
[PubMed - indexed for MEDLINE]
2.

BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.

Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F.

Osteoporos Int. 2005 Aug;16(8):943-52. Epub 2005 Mar 1.

PMID:
15739035
[PubMed - indexed for MEDLINE]
3.

Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G.

Med Sci Monit. 2011 Aug;17(8):CR442-448.

PMID:
21804463
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

PMID:
15068497
[PubMed - indexed for MEDLINE]
5.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
[PubMed - indexed for MEDLINE]
6.

Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.

Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V.

Clin Endocrinol (Oxf). 2003 Mar;58(3):365-71.

PMID:
12608943
[PubMed - indexed for MEDLINE]
7.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
[PubMed - indexed for MEDLINE]
8.

Relation of BsmI vitamin D receptor gene polymorphism to bone mineral density and occurrence of osteoporosis in postmenopausal Chinese women in Taiwan.

Chen HY, Chen WC, Hsu CD, Tsai FJ, Tsai CH, Li CW.

Osteoporos Int. 2001 Dec;12(12):1036-41.

PMID:
11846330
[PubMed - indexed for MEDLINE]
9.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
[PubMed - indexed for MEDLINE]
10.

The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype.

Graafmans WC, Lips P, Ooms ME, van Leeuwen JP, Pols HA, Uitterlinden AG.

J Bone Miner Res. 1997 Aug;12(8):1241-5.

PMID:
9258754
[PubMed - indexed for MEDLINE]
11.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

PMID:
18003959
[PubMed - indexed for MEDLINE]
Free Article
12.

Association of physical activity and bone: influence of vitamin D receptor genotype.

Blanchet C, Giguère Y, Prud'homme D, Dumont M, Rousseau F, Dodin S.

Med Sci Sports Exerc. 2002 Jan;34(1):24-31.

PMID:
11782643
[PubMed - indexed for MEDLINE]
13.

The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.

Rheumatol Int. 2005 Nov;26(1):21-9. Epub 2005 Feb 2.

PMID:
15688191
[PubMed - indexed for MEDLINE]
14.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
[PubMed - indexed for MEDLINE]
15.

BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.

Lambrinoudaki I, Kaparos G, Armeni E, Alexandrou A, Damaskos C, Logothetis E, Creatsa M, Antoniou A, Kouskouni E, Triantafyllou N.

Eur J Neurol. 2011 Jan;18(1):93-8. doi: 10.1111/j.1468-1331.2010.03103.x.

PMID:
20500803
[PubMed - indexed for MEDLINE]
16.

The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG 3rd, Bilezikian JP.

J Clin Endocrinol Metab. 2011 Aug;96(8):2441-9. doi: 10.1210/jc.2010-2855. Epub 2011 May 18.

PMID:
21593114
[PubMed - indexed for MEDLINE]
17.

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.

Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K.

J Rheumatol. 2010 Jan;37(1):141-8. doi: 10.3899/jrheum.090411. Epub 2009 Nov 16.

PMID:
19918047
[PubMed - indexed for MEDLINE]
18.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818
[PubMed - indexed for MEDLINE]
19.

The role of vitamin D receptor gene polymorphisms in the bone mineral density of Greek postmenopausal women with low calcium intake.

Stathopoulou MG, Dedoussis GV, Trovas G, Theodoraki EV, Katsalira A, Dontas IA, Hammond N, Deloukas P, Lyritis GP.

J Nutr Biochem. 2011 Aug;22(8):752-7. doi: 10.1016/j.jnutbio.2010.06.007. Epub 2010 Nov 5.

PMID:
21115334
[PubMed - indexed for MEDLINE]
20.

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group.

Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12.

PMID:
20938767
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk